ConductScience.org, home
AKR1C3: aldo-keto reductase family 1 member C3
API referenceFor AI assistants

Gene · 8644

Papers2,828

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

1 to 20 of 2,828

Download this page as JSON
TitleJournalYearPMIDFound bySource
Network toxicology and machine learning analysis of MC-LR-associated hepatocellular carcinoma.J Environ Sci Health B202642811799PubTator, text miningPubMed
Metabolomics and network pharmacology identify three key bioactive organic acid metabolites in Amomum tsao-ko.Genomics202642764030PubTator, text miningPubMed
Integrating target prediction and transcriptomic analysis identifies the AKR1C2-KRT8 axis in rotenone-induced dopaminergic neuron injury.Brain Res Bull202642679909PubTator, text miningPubMed
Integrated computational analysis prioritizes candidate targets and pathways linking ochratoxin A exposure to hepatocellular carcinoma.PLoS One202642672059PubTator, text miningPubMed
Triphala Targets the SLC7A11-GSH-GPX4 Axis to Trigger Ferroptosis in Oral Cancer: An Integrated Network Pharmacology, Molecular Docking, and Experimental Validation Study.Chem Biol Drug Des202642644728PubTator, text miningPubMed
Identification of candidate macrophage-ferroptosis crosstalk genes associated with immune infiltration in myocardial infarction: A bioinformatics analysis.PLoS One202642640988PubTator, text miningPubMed
Cotinine enhances androgen receptor stability and promotes androgen-dependent proliferation in prostate cancer cells: An in vitro study.Arch Biochem Biophys202642617929PubTator, text miningPubMed
Synthesis and Activity-Based Protein Profiling Identifies Aldo-Keto Reductase 1C3 as Target Protein of Myxoglucamides.Angew Chem Int Ed Engl202642573019PubTator, text miningPubMed
Integrated computational and in vitro investigation to explore the preliminary anti-proliferative and anti-mitotic potential of γ-oryzanol against breast cancer.Naunyn Schmiedebergs Arch Pharmacol202642525294PubTator, text miningPubMed
Naringin sensitizes nasopharyngeal carcinoma cells to paclitaxel by inducing AKR1C3 expression.J Int Med Res202642523162PubTator, text miningPubMed
Design, Synthesis, and Biological Evaluation of a Cathepsin B-Activated Small Molecule-Drug Conjugate Targeting AKR1C3 to Enhance Chemotherapeutic Selectivity.J Med Chem202642470376PubTator, text miningPubMed
Anticancer, hepatoprotective, and mechanistic evidence of chlorogenic acid in liver cancer: A systematic review.Biomed Pharmacother202642468210PubTator, text miningPubMed
AKR1C3 and CLIC3 mediate the comorbidity of diabetic foot ulcers and hypercholesterolemia via the TGF-β/lipid metabolism axis.Biochem Biophys Res Commun202642462461PubTator, text miningPubMed
Sulfonylureas beyond diabetes: A comprehensive review on anticancer and off-target effects (1956-2025).Eur J Med Chem202642437555PubTator, text miningPubMed
AKR1C3 inhibitors and exploiters for the treatment and therapeutic monitoring of cancer: a patent review (2020-present).Expert Opin Ther Pat202642396977PubTator, text miningPubMed
Phase 2 dose-expansion trial of OBI-3424, a DNA-alkylating prodrug, in patients with advanced solid tumors expressing AKR1C3.Oncologist202642390142PubTator, text miningPubMed
METTL3 Promotes Castration-Resistant Prostate Cancer Progression by Enhancing AKR1C3 Expression.J Biochem Mol Toxicol202642365614PubTator, text miningPubMed
Rational design and structural insights of osthole-derived selective AKR1C3 inhibitors with cellular activity.Bioorg Chem202642335733PubTator, text miningPubMed
Target-driven machine learning-enabled virtual screening (TAME-VS) enables prioritization of AKR1C3 inhibitors.Commun Chem202642297903PubTator, text miningPubMed
From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer.Front Immunol202642292383PubTator, text miningPubMed

gene-search-2026-11-11-0.2.0

Next page

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/genes/v1/8644/papers

API referenceFor AI assistants